Search

Your search keyword '"Maestro, Alessandra"' showing total 13 results
Start Over Author "Maestro, Alessandra" Publisher mdpi ag
13 results on '"Maestro, Alessandra"'

3. Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study

Author

Maximova, Natalia, primary, Nisticò, Daniela, additional, Riccio, Guglielmo, additional, Maestro, Alessandra, additional, Barbi, Egidio, additional, Faganel Kotnik, Barbara, additional, Marcuzzi, Annalisa, additional, Rimondi, Erika, additional, and Di Paolo, Antonello, additional

Published
2023
Full Text
View/download PDF

6. Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis

Author

Baldo, Francesco, primary, Simeone, Roberto, additional, Marcuzzi, Annalisa, additional, Grasso, Antonio Giacomo, additional, Vidimari, Rossella, additional, Ciriello, Francesca, additional, Zanon, Davide, additional, Maestro, Alessandra, additional, Barbi, Egidio, additional, and Maximova, Natalia, additional

Published
2021
Full Text
View/download PDF

12. Pentaglobin® Efficacy in Reducing the Incidence of Sepsis and Transplant-Related Mortality in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study

Author

Davide Zanon, Lucio Torelli, Egidio Barbi, Giorgia Carlone, Natalia Maximova, Alessandra Maestro, Carlone, Giorgia, Torelli, Lucio, Maestro, Alessandra, Zanon, Davide, Barbi, Egidio, and Maximova, Natalia

Subjects
medicine.medical_specialty, medicine.medical_treatment, Pentaglobin®, lcsh:Medicine, Hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, pediatric patients, aplasia, infection-related mortality rate, Article, Sepsis, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, business.industry, Standard treatment, Mortality rate, Incidence (epidemiology), lcsh:R, Retrospective cohort study, General Medicine, Aplasia, Transplant-Related Mortality, medicine.disease, surgical procedures, operative, 030220 oncology & carcinogenesis, business, pediatric patient, 030215 immunology
Abstract

The 12-month mortality rate in patients undergoing hematopoietic stem cell transplantation (HSCT) remains high, especially with respect to transplant-related mortality (TRM), which includes mortality due to infection complications through the aplasia phase. The aim of this study was to determine whether the administration of Pentaglobin&reg, could decrease TRM by lowering sepsis onset or weakening sepsis through the aplasia phase. One hundred and ninety-nine pediatric patients who had undergone HSCT were enrolled in our retrospective study. The patients were divided into two groups: the Pentaglobin group, which had received Pentaglobin&reg, in addition to the standard antibiotic treatment protocol established for the aplasia phase, and the Control group, which received only the standard treatment. As compared to the control group outcome, Pentaglobin&reg, led to a significant decrease in the days of temperature increase (p &lt, 0.001) and a reduced infection-related mortality rate (p = 0.04). In addition, the number of antibiotics used to control infections, and the number of antibiotic therapy changes needed following first-line drug failure, were significantly lowered in the Pentaglobin group as compared to the control group (p &lt, 0.0001). With respect to the onset of new infections following the primary infection detected, the Pentaglobin group showed a significant reduction for bacterial events, as compared to the control group (p &lt, 0.03). Pentaglobin&reg, use in patients undergoing HSCT seems to produce a significant decrease in infection-associated TRM rate.

Published
2020

13. Pentaglobin ® Efficacy in Reducing the Incidence of Sepsis and Transplant-Related Mortality in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study.

Author

Carlone G, Torelli L, Maestro A, Zanon D, Barbi E, and Maximova N

Abstract

The 12-month mortality rate in patients undergoing hematopoietic stem cell transplantation (HSCT) remains high, especially with respect to transplant-related mortality (TRM), which includes mortality due to infection complications through the aplasia phase. The aim of this study was to determine whether the administration of Pentaglobin ® could decrease TRM by lowering sepsis onset or weakening sepsis through the aplasia phase. One hundred and ninety-nine pediatric patients who had undergone HSCT were enrolled in our retrospective study. The patients were divided into two groups: the Pentaglobin group, which had received Pentaglobin ® in addition to the standard antibiotic treatment protocol established for the aplasia phase, and the Control group, which received only the standard treatment. As compared to the control group outcome, Pentaglobin ® led to a significant decrease in the days of temperature increase ( p < 0.001) and a reduced infection-related mortality rate ( p = 0.04). In addition, the number of antibiotics used to control infections, and the number of antibiotic therapy changes needed following first-line drug failure, were significantly lowered in the Pentaglobin group as compared to the control group ( p < 0.0001). With respect to the onset of new infections following the primary infection detected, the Pentaglobin group showed a significant reduction for bacterial events, as compared to the control group ( p < 0.03). Pentaglobin ® use in patients undergoing HSCT seems to produce a significant decrease in infection-associated TRM rate.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results